Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma.
-
Authors
-
-
Goldschmidt, Hartmut1
-
Dimopoulos, Meletios A2
-
Rajkumar, S Vincent3
-
Weisel, Katja C4
-
Moreau, Philippe5
-
Chng, Wee-Joo6, 7
-
Mikala, Gábor8
-
Cavo, Michele9
-
Ramasamy, Karthik10
-
Suryanarayan, Kaveri11
-
Teng, Zhaoyang11, 12
-
Labotka, Richard11
-
Mateos, Maria Victoria13
-
1
Internal Medicine V and National Center for Tumor Diseases (NCT), University Clinic Heidelberg, Heidelberg, Germany. [email protected]
,
(Germany)
-
2
Hematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
,
(Greece)
-
3
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
-
4
Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
,
(Germany)
-
5
Department of Hematology, University Hospital Hôtel Dieu, University of Nantes, Nantes, France.
,
(France)
-
6
Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore.
,
(Singapore)
-
7
Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
,
(Singapore)
-
8
South Pest Central Hospital, National Institute for Hematology and Infectious Diseases, Budapest, Hungary.
,
(Hungary)
-
9
Seràgnoli Institute of Hematology, University of Bologna, Bologna, Italy.
,
(Italy)
-
10
Oxford University Hospitals, NHS Foundation Trust, Oxford Myeloma Centre for Translational Research, Oxford, UK.
-
11
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
-
12
Servier Pharmaceuticals, Boston, MA, USA.
-
13
Hematology, Hospital Universitario de Salamanca, University Hospital of Salamanca, IBSAL, CIC, IBMCC (USAL-CSIC), Salamanca, Spain.
,
(Spain)
- Type
- Published Article
- Journal
-
Leukemia
- Publisher
-
Springer Nature
- Publication Date
-
Nov 01, 2020
- Volume
-
34
- Issue
-
11
- Pages
-
3019–3027
- Identifiers
-
DOI: 10.1038/s41375-020-0819-8
-
PMID: 32327729
- Source
-
Medline
- Language
-
English
- License
-
Unknown
Abstract
In the TOURMALINE-MM3 study, post-autologous stem cell transplantation maintenance therapy with the oral proteasome inhibitor ixazomib versus placebo significantly improved progression-free survival (PFS), with a favorable safety profile. With ixazomib versus placebo maintenance, deepening responses occurred in 139/302 (46%) versus 60/187 (32%) patients with very good partial response or partial response (VGPR/PR) at study entry (relative risk 1.41, P = 0.004), and median time to best confirmed deepened response was 19.9 versus 30.8 months (24-month rate: 54.2 versus 41.4%; hazard ratio (HR): 1.384; P = 0.0342). Median PFS in patients with VGPR/PR at study entry was 26.2 versus 18.5 months (HR: 0.636, P < 0.001) with ixazomib versus placebo; in a pooled analysis across arms, in patients with versus without deepening responses, the median PFS was not reached versus 15.9 months (HR: 0.245, P < 0.001). In patients with deepening responses, 24-month PFS rate was 77.4 versus 68.3% with ixazomib versus placebo (HR: 0.831; P = 0.466); in patients without deepening responses, median PFS was 17.9 versus 14.1 months (HR: 0.741; P = 0.028). These analyses demonstrate the significantly higher rate of deepening responses with ixazomib versus placebo maintenance and the association between deepening response and prolonged PFS.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 11/12/2020 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at
https://www.ncbi.nlm.nih.gov/pubmed/32327729
